AstraZeneca PLC (AZNCF)
| Previous close | 140.15 |
| Open | 138.06 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 133.20 - 138.24 |
| 52-week range | 118.16 - 153.10 |
| Volume | |
| Avg. volume | 3,025 |
| Market cap | 214.302B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 36.28 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.86 (2.04%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
- Business Wire
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
- Business Wire
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
WILMINGTON, Del., April 11, 2024--AstraZeneca’s FASENRA® (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with severe asthma aged 6 to 11 with an eosinophilic phenotype.1 FASENRA was first approved in 2017 as an add-on maintenance for the treatment of severe eosinophilic asthma (SEA) in patients aged 12 and older.1
- Business Wire
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
TOKYO & BASKING RIDGE, N.J., April 06, 2024--ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2+ Solid Tumors
